Rosiglitazone maleate

Rosiglitazone maleate is an insulin sensitizer. Rosiglitazone maleate activates luciferase-based expression constructs PPARγ1 and PPARγ2 with EC50 values of approximately 30 nM and 100 nM, respectively. Rosiglitazone maleate (Avandia) improves glycemic control while reducing circulating insulin levels. Rosiglitazone maleate also appears to have an anti-inflammatory effect in addition to its effect on insulin resistance. Rosiglitazone maleate is active in vivo as an antidiabetic agent in the ob/ob mouse model, and has been used as an oral hypoglycemic agent in the treatment of Type II diabetes in humans for many years.